CD40 Agonist-CD40L Fusion Proteins for Single-Agent Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CD40-targeting strategies for enhancing immune responses to antigens, such as viral or cancer antigens, require co-administration of Toll-like receptor activating agents like poly IC, and there is a need for single molecules with high potency as agonist vehicles to improve in vivo efficacy.
Innovation Solution
A recombinant CD40 activating protein is developed, comprising a CD40 agonist antibody fused or linked to the CD40 ligand (CD40L), which induces immune responses and enhances CD40 activation efficacy, potentially replacing the need for separate agents like poly IC.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If agonistic anti-CD40 antibodies are used to activate APCs and stimulate immune responses, then immune response is enhanced, but in vivo efficacy requires co-administration of Toll-like receptor activating agents such as poly IC
Solution Approach 1:
The patent combines CD40 agonist antibody and CD40L into a single fusion protein molecule. This merging of two separate therapeutic agents into one molecule eliminates the need for co-administration of poly IC, resolving the contradiction between maintaining in vivo efficacy and simplifying the administration regimen.
Solution Approach 2:
The fusion protein performs multiple functions simultaneously: it activates CD40 on APCs through the antibody portion and provides CD40L binding through the ligand portion. This multi-functionality in a single molecule replaces the need for multiple separate agents, addressing the technical contradiction.
2Ease of operation
If CD40 agonist antibody is used alone, then the administration regimen is simple, but in vivo efficacy is insufficient without co-administration of poly IC
Solution Approach 1:
By merging CD40 agonist antibody and CD40L into a single fusion protein, the patent achieves both simplicity in administration (single agent) and high in vivo efficacy (no poly IC needed), directly resolving this contradiction.
3Reliability
If separate agents (CD40 agonist antibody and poly IC) are co-administered, then in vivo efficacy is achieved, but the treatment requires multiple agents and complex administration
Solution Approach 1:
The fusion protein consolidates the functions of multiple agents into a single molecule, reducing the quantity of substances required from two or more separate agents to one unified therapeutic agent.
Solution Approach 2:
The single fusion protein molecule performs multiple therapeutic functions that previously required separate agents, eliminating the need for co-administration and reducing the number of substances required.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CD40 activating protein exhibits superior potency in inducing cytokine secretion and CD86 surface expression, comparable or superior to combined administration of CD40 agonist antibodies and CD40L, effectively stimulating immune responses without additional agents.
Implementation Method 1
CD40 is a potent activating tumor necrosis factor receptor superfamily member expressed on antigen-presenting cells (APCs) and B cells
Implementation Method 2
Dendritic cells (DCs) respond to infections by internalizing antigens and activating pathogen-associated molecular patterns (PAMPs), and thus present foreign antigens on their major histocompatibility complex (MHC) molecules to antigen-specific T cells, initiating a cycle of DC maturation via CD40 ligand (CD40L) expressed on the activated T cell
Implementation Method 3
Beyond primary screening to identify CD40-reactive monoclonal antibodies that have the most potent agonist activity, e.g., inducing cytokine secretion or CD86 surface expression on human DCs
Implementation Method 4
inducing cytokine secretion or CD86 surface expression on human DCs
Data Source
AI summary
CD40 activating proteins comprising recombinant proteins with CD40 agonist antibodies or their antigen-binding fragments fused or linked to CD40 ligand are provided. The CD40 activating proteins may further comprise at least one antigen. Uses for the CD40 activating proteins include inducing immune responses directed to delivered antigens such as viral or cancer antigens. Properties of the CD40 activating protein may include the ability to induce proliferation of B cells or secretion of cytokines, such as IL-6, IL-12 and/or IL-15.